Takhzyro Found Safe, Effective for HAE Over Long Term in Real-world Study

About one year of treatment with Takhzyro (lanadelumab) safely and effectively lowered the frequency of swelling attacks, while improving quality of life and treatment satisfaction in people with hereditary angioedema (HAE), according to interim data from the real-world EMPOWER study. In addition, nearly 1 in 5 patients was able to…

Takhzyro With Long-term Use Safely Prevents HAE Attacks, Study Finds

Takhzyro (lanadelumab) safely and markedly reduced the frequency of swelling attacks in people with hereditary angioedema (HAE) over 2.5 years, according to results of the HELP open-label extension (OLE) study. “This study supports the use of Takhzyro as a long-term preventative treatment option for those 12 years of…